Navigation Links
Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
Date:9/20/2007

- Phase III data published in the American Journal of Nephrology -

DEERFIELD, Ill., Sept. 20 /PRNewswire-FirstCall/ -- Astellas Pharma US, Inc. today announced that its Phase III data on VAPRISOL was published in the September issue of the American Journal of Nephrology. In this study, VAPRISOL showed a significant increase in serum sodium concentrations in patients with hyponatremia -- a potentially life-threatening condition that occurs when the body's sodium level falls below normal.

"This study demonstrated that VAPRISOL 40 mg/day significantly increased serum [Na+] in patients with euvolemic or hypervolemic hyponatremia," said Joseph G. Verbalis, M.D., at the Georgetown University Hospital. "VAPRISOL will likely address an important clinical need for euvolemic or hypervolemic hyponatremia in hospitalized patients."

VAPRISOL is the first in a new class of arginine vasopressin (AVP) receptor antagonists. VAPRISOL blocks both V1a and V2 vasopressin receptors, resulting in increased urine output without increased sodium loss. This effect, known as "aquaresis," increases serum sodium levels and helps to restore salt and water balance in patients with hyponatremia due to increased body water (dilutional hyponatremia).

VAPRISOL is approved by the U.S. Food and Drug Administration as a treatment for euvolemic and hypervolemic hyponatremia in hospitalized patients. VAPRISOL is not indicated for the treatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. The approved doses for VAPRISOL include 20 mg/day and 40 mg/day. The 80 mg/day dose used in this study is not an approved dose.

In the double-blind, multicenter study, 84 patients with serum sodium levels of 115 to <130 mEq/L were randomized to receive placebo or a 20-mg intravenous bolus of conivaptan, fo
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Two mass spectrometry technologies MALDI ... their effectiveness is established, according to biotechnology ... says that while mass spectrometry (mass spec ... in proteomic biomarker discovery and validation, mass ... techniques has struggled to elucidate molecular distribution ...
(Date:2/26/2015)... -- Today the National Safety Council released a ... effects of pain medications , debunking ... Oxycontin, are safer options than over-the-counter pain relievers. ... on heroin and cocaine combined," said Deborah A.P. ... medications are marketed as the Cadillac option for treating ...
(Date:2/26/2015)... 2015 Every year many millions of donations ... disease.  Nevertheless, year after year doctors and the medical ... first test to determine the status of heart health ... not, even though that technology is over 100 years ... doctors know, (while most patients do not know) that ...
Breaking Medicine Technology:Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2National Heart Health Month In February 2
(Date:2/28/2015)... 28, 2015 The World Scout League ... materials to potential EMTs and firefighters, recently announced its ... a way to raise charitable donations for age-related research. ... Columbia, will be held on March 29, 2015; registration ... begin at 3:30 p.m. , To participate in ...
(Date:2/28/2015)... 2015 1Heart Caregiver Services CEO ... brand at Houston Texas Franchise Expo South and ... its executive delegates headed by Vice-President of Operations ... Training Randolph Clarito. , Franchise Expo South, sponsored ... February 4-7 and featured Franchise brands of every ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Wireless ... management services, and one of the founders ... support for Bell Mobility within their CLEAN Platform™ ... services. Wireless Analytics’ newly developed Bell Mobility ... for the Canadian wireless carrier’s business customers. , ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 A ... found a correlation between men who cycle on a regular ... overall health, the study suggests that the more hours per ... to develop prostate cancer, leading to an increased importance on ... it allows physicians to look more closely at patents’ risk ...
(Date:2/27/2015)... February 27, 2015 Those ... are often misunderstood, misdiagnosed and therefore aren’t ... healthy lives. Jacksonville-based addiction treatment center ... its highly acclaimed Lakeview Professional Lecture Series ... in understanding this complicated condition. ...
Breaking Medicine News(10 mins):Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2
... , ... ... ... ...
... , ... ... ... , ...
... , ... ... ... ...
... ... ... ... ...
... ranked among the top hospitals in the world in ... Loyola was tied for the top nine programs in ... Awards competition sponsored by the United States and Canadian ... participated in the competition. Medical students, residents, ...
... with rats, tea consumption reduced oxidative stress, researchers say , ... tea work their way into the tissues of the eye ... say. , The findings, published in the current issue ... suggest that the substances, known as catechins, are absorbed by ...
Cached Medicine News:Health News:Labopharm announces underwriters' exercise of over-allotment option for recent public offering 2Health News:Labopharm announces underwriters' exercise of over-allotment option for recent public offering 3Health News:Labopharm announces underwriters' exercise of over-allotment option for recent public offering 4Health News:Labopharm announces underwriters' exercise of over-allotment option for recent public offering 5Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 2Health News:WebMD to Present at the Goldman Sachs Technology and Internet Conference 2010 3Health News:Cunard's Queen Victoria is 'Pretty in Pink' in Sydney 2Health News:GSI Group Reports Preliminary Fourth Quarter 2009 Bookings, and Cash Balance 2Health News:GSI Group Reports Preliminary Fourth Quarter 2009 Bookings, and Cash Balance 3Health News:GSI Group Reports Preliminary Fourth Quarter 2009 Bookings, and Cash Balance 4Health News:GSI Group Reports Preliminary Fourth Quarter 2009 Bookings, and Cash Balance 5Health News:GSI Group Reports Preliminary Fourth Quarter 2009 Bookings, and Cash Balance 6
... HF35-50 High Frequency Ultrasound system is the ... frequency system available. The HF35-50 allows users ... the anterior segment with 35MHz or 50MHz ... with a 20 MHz sealed B-probe. , ...
... accurate digital A-scan system. The combination of ... fast precise algorithm enables scan capture immediately ... visual axis. The A5500 A-scan provides: live ... thermal printer, 5 different examination modes, measurement ...
... The Microscan 100A+ is extremely portable, ... kg). The digital A-scan system provides a ... a high frequency, low noise probe and ... upon application of the probe along the ...
... workstation. Accurate, efficient and easy to use. ... a variety of regressive, theoretical, and adaptive ... of the patient. Convenient design features improve ... for hands-free operation, audible tone to minimize ...
Medicine Products: